Fig. 1.

The differential response patterns within our clinical trials indicate the therapies’ systems biological activity. Understanding systems biology as adjustable size may break through the barrier of complex tumor–stroma-interactions in a therapeutically relevant way: Comparatively high efficacy at moderate toxicity. Structured systems-directed therapies in metastatic cancer may get a source for detecting tumor-associated complex aggregated action effects as adjustable sizes available for targeted biomodulatory therapies